Geneva, May 29 -- International Clinical Trials Registry received information related to the study (ChiCTR2600125129) titled 'Efficacy Study of Maximally Complete TURBT Followed by Combination Therapy with Disitamab Vedotin, Tislelizumab, and Epirubicin Intravesical Instillation for Bladder-Preserving Treatment in Muscle-Invasive Bladder Cancer' on May 21.
Study Type: Interventional study
Study Design:
Single arm
Primary Sponsor: The First Affiliated Hospital of Sun Yat-sen University
Condition:
Bladder Cancer
Recruitment Status: Not Recruiting
Phase: 2
Date of First Enrollment: 2026-06-01
Target Sample Size: Trial group:34;
Countries of Recruitment:
China
To know more, visit https://www.chictr.org.cn/showproj.html?proj=31...